 |
 |
VRS-859:
Glucagon-like peptide-1 analog |
Indication(s): |
| Type 2 diabetes |
Development Status: |
| Phase 1 clinical trials in patients with T2DM (enrollment completed) |
| |
|
|
 |
| Diartis Pharmaceuticals is developing products for metabolic disease. The company is interested in exploring partnerships on these products to accelerate the development process and ensure successful commercialization. |
 |
 |
Diartis Pharmaceuticals, Inc.
275 Shoreline Drive, Suite 450
Redwood City, CA 94065
(650) 963 8595 |
|
|
